The effect of stem cell transplantation in the treatment of COVID-19
- Conditions
- COVID-19.Severe Acute Respiratory Syndrome coronavirusRA01.0
- Registration Number
- IRCT20140528017891N8
- Lead Sponsor
- MOM research and innovation center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Patients in acute phase
Laboratory confirmation of SARS-COV-2 infection
Pneumonia confirmed by chest x-ray or tomography
Respiratory rate> 30 times / minute
Oxygen Saturation less than 93%
Arterial oxygen partial pressure (Pao2) /oxygen inhalation(Fio2) less than 300 mmHg
No history of tumor or malignant disease
Pregnant patient with a positive pregnancy test or during lactation or who is planning to become pregnant during the study
The definitive history of acquired or inherited immune deficiency diseases
The definitive psychotic illness A history of serious mental illness or a history of suicide
The use of NG tube
Creatinine greater than 1.7 or hepatic enzymes three times normal or white blood cell count lower than 3000 and hemoglobin less than 10
Co-infection of human immunodeficiency viruses, Hepatitis B, Hepatitis C and Human T-lymphotropic virus
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death. Timepoint: Up to 28 days after starting the study. Method of measurement: Patient observation and evaluation of vital signs.
- Secondary Outcome Measures
Name Time Method Evaluation of Pneumonia Severity Index. Timepoint: Up to 28 days. Method of measurement: PSI.;Evaluation of oxygen supply index. Timepoint: Discharge from ICU. Method of measurement: Pulse Oximeter.;C- Reactive protein. Timepoint: 28 days or until the marker is normalized. Method of measurement: Blood sample.;Procalcitonin. Timepoint: Until the marker is normalized. Method of measurement: Blood sample.;Lymphocyte count. Timepoint: Until the marker is normalized. Method of measurement: CBC.;Counting of CD3 +, CD4 + and CD8 + T cells. Timepoint: Before the first injection and after the third injection. Method of measurement: Flow cytometry.;+ CD4 + / CD8 ratio. Timepoint: Before the first injection and after the third injection. Method of measurement: Flow cytometry.;Improve pneumonia evaluated by CT scan. Timepoint: After the second and third infusions. Method of measurement: CT scan.